Comprehensive supply chain solutions for the Life Sciences
CryoPortal Login
  • English
    • Español (Spanish)
    • Français (French)
    • 日本語 (Japanese)
    • 简体中文 (Chinese)
Cryoport Systems logo
  • Industry Expertise
    • Cell Therapy
    • Gene Therapy
    • Biologics
    • Reproductive Medicine
      • Intended Parents
      • Clinics
    • Animal Health
      • Pharma & Biotech
      • Livestock
      • Companion Animal
  • Trusted Solutions
    • Shipping Systems
      • Cryogenic (below -150°C) Shipping Systems
        • Cryoport Express® Cryogenic Standard Shipping System
        • Cryoport Express® Cryogenic Combo Shipping System
        • Cryoport Express® Cryogenic HV3 Shipping System
        • Cryomax® Cryogenic Shipping System
      • Ultra Cold (-60 to -80°C) Shipping Systems
        • Cryoport Elite® Ultra Cold
      • Refrigerated (2 to 8°C) and CRT (15 to 25°C) Shipping Systems
        • Cryoport Express® C3™ Shipping System
      • Cryoport Accessories
        • Cryoport Safepak® System
    • Transportation
      • Clinical Drug Distribution
      • Commercial Drug Distribution
      • Cryoshuttle®
      • Reproductive Medicine Distribution
      • Animal Health Distribution
    • BioServices
      • Controlled Temperature Storage
      • Drug Packaging and Labelling
      • Kit Production
      • Biobanking
      • Clinical Sample Management
      • Drug Return & Destruction
      • Regulatory & QP Services
    • Consulting Services
      • Shipping Risk Assessment and Shipping Lane Qualification
      • Shipping System and Packaging Performance Qualification
      • Project/Program Management
      • Custom Packaging and Accessory Development
    • IntegriCell™ Cryopreservation
    • Data Services
  • Next-Gen Innovation
    • Cryoportal® 2
    • Cryoport Elite®
    • IntegriCell™ Cryopreservation
    • Integrated Supply Chain Centers
  • About Us
    • Our People
    • Management
    • Quality
    • Careers
    • Cryoport’s Family of Companies
  • Resources
    • Events
    • Supply Chain Blog
    • Company News & Articles
    • Brochures and Spec Sheets
    • Instructions
    • White Papers and Case Studies
    • Videos/Webinars
    • Reference Materials
      • Cryoportal® 2 Training Materials
      • Validation Package Request
      • Data Station Direction & Validation
      • Quality Change Notification Request
      • Smartpak II™ Airline Authorizations
  • Contact Us
    • Request a Quote
    • Locations
  • CYRX
CryoPortal Login
Request Info
Request a Quote
Request a Quote
Request Info Request a Quote

Supply Chain Archives

06/13/2025

Expanding Clinical Trials Internationally in the ATMP Space

Expanding an advanced therapy clinical trial internationally is an exciting milestone but can be daunting for researchers and biotech teams. International trials involve challenges like country-specific regulations, Qualified Person (QP) release, and complex logistics. Early planning for these issues can help avoid delays and ensure progress.

Read More

Read More
06/04/2025

Engineering for Impact: A Conversation with Mike Dybicz on the HV3 and Safepak Systems

When it comes to cell and gene therapy (CGT) logistics, innovation is about more than improving efficiency, it’s about safeguarding a patient’s only chance at treatment. We sat down with Mike Dybicz, Senior Vice President & Chief Product Development Officer, to discuss how Cryoport Systems is reshaping the future of CGT logistics with innovative products such as Cryoport Express® Cryogenic HV3 Shipping System and Safepak® System 1800, designed specifically to reduce risk, increase reliability, and ultimately improve patient outcomes. 

Read More

Read More
06/01/2025

Honoring Survivors, Enabling the Future

Each year on the first Sunday in June, National Cancer Survivors Day serves as a powerful reminder that behind every innovation in medicine, every breakthrough treatment, and every clinical milestone, there are human stories of courage, resilience, and hope. At Cryoport Systems, we pause today not only to recognize the strength of cancer survivors but also to reflect on how our work supports the treatments that are changing survival outcomes. 

Read More

Read More
05/29/2025

Starting Smart: How to Structure an Integrated Supply Chain in Early-Stage CGT Programs

For many academic labs, technology spinouts, and early-stage CGT companies, the temperature-controlled supply chain feels like something to figure out later. But when dealing with highly sensitive starting materials and therapies like CGTs, later can quickly become too late. Whether you’re preparing for first-in-human trials or just beginning to plan for scale, integrated thinking now can spare you time, cost, and complexity later.

Read More

Read More
05/19/2025

Clinical Trials Day: Supporting the Journey from Discovery to Delivery

Clinical trials represent hope, innovation, and the pursuit of better outcomes. They are the backbone of developing new diagnostics, vaccines, devices, and therapies. They help ensure safety, efficacy, and accessibility to the people who need them. That's why each year on May 20, the community comes together to celebrate Clinical Trials Day, honoring the anniversary of the first randomized clinical trial. At Cryoport Systems, we are honored to support our partners and clients in this journey.

Read More

Read More
04/29/2025

Optimizing Cryopreservation for Leukapheresis: Advancing Cell and Gene Therapy Supply Chains

The supply chain for fresh leukapheresis is one of the most complex logistical challenges in cell and gene therapy (CGT). As a critical starting material, leukapheresis must be collected from donors, processed, and transported within a limited time window. These challenges increase variability and risk, ultimately impacting the success of advanced therapies. Alexandre Michaux, Process Development & MSAT Manager at IntegriCell™ , recently presented his work on the development of an automated cryopreservation process for leukapheresis in a Poster Presentation at Advanced Therapies Congress in London.

Read More

Read More
04/22/2025

Advancing Standardization in Cell and Gene Therapy Supply Chains

The future of cell and gene therapy depends not only on scientific advancements but also on the efficiency and reliability of its supply chain. In a recent panel discussion at Advanced Therapies Congress in London, industry experts explored the critical need for standardization, the challenges in achieving it, and the opportunities to improve logistics, manufacturing, and delivery systems.

Read More

Read More
04/18/2025

Transforming Patient Access to CGT: Q&A with Aruna Mor

Aruna Mor, Chief Commercial Officer at Cryoport Systems, recently delivered a powerful keynote at Advanced Therapies Congress in London, shedding light on the complexities of patient access and the critical steps needed to overcome these barriers. We sat down with her to delve deeper into some of the key themes of her keynote, exploring the intersection of science, logistics, supply chain, regulation, and collaboration that will determine the future of Cell and Gene Therapy (CGT).

Read More

Read More
04/14/2025

Enabling the Outcome Through Enhancing Patient Accessibility

Cell and Gene Therapy (CGT) has emerged as one of the most transformative areas in modern medicine, shaping the future of healthcare and changing the face of next-generation therapeutic approaches. Yet, despite the continued scientific progress, a critical challenge persists in ensuring these therapies are accessible to the patients who need them most. This challenge was the focus of the keynote address at the Advanced Therapies Congress in London, delivered by Aruna Mor, Chief Commercial Officer at Cryoport Systems, where she spoke about to the state of patient access within the field of advanced therapeutics.

Read More

Read More
03/24/2025

Strengthening Global ATMP Logistics: How Cryoport Systems’ Netherlands Facility Supports Temperature-Controlled Supply Chains

The success of ATMPs depends on more than just scientific breakthroughs, it requires a highly controlled, risk-mitigated supply chain that ensures product integrity from research through commercialization. With cell and gene therapies moving across multiple clinical sites, manufacturing facilities, and regulatory jurisdictions, developers need a logistics partner that can support seamless, temperature-controlled supply chain management at a global scale. 

Read More

Read More
Load More

Categories

  • All (60)
  • Industry Insights (17)
  • Managing the Cold Chain (20)
  • Navigating Logistics (22)
  • Patient Access and Awareness (6)

Tags

  • Asia
  • Biologics
  • BioServices
  • Biostorage
  • Cell Therapy
  • Clinical Trials
  • Cold Chain Management
  • Commercialization
  • Cryopreservation
  • Europe
  • Gene Therapy
  • Global Logistics Tracking
  • Global Supply Chain Management
  • International Shipping
  • North America
  • Risk Mitigation
  • Standards and Compliance
  • Supply Chain Management

Subscribe to our newsletter

Never miss another update! Join our mailing list for all the latest news, events, and announcements.

  • Clinical Trial icon Trusted with 711 clinical trials
  • Approved therapies icons Supporting 18 approved therapies
  • Quality icon Robust quality standards
  • Client service icon 24/7/365 support team
  • About Us
  • Industries
  • Solutions
  • Resources
  • Innovation
  • Contact Us
  • About Us
  • Industries
  • Solutions
  • Resources
  • Innovation
  • Contact Us
Cryoport Systems logo
  • Privacy Policy
  • Terms of Use
  • Careers
Request a Quote
  • youtube
  • twitter
  • linkedin
Cryoport Systems logo

© 2024 Cryoport Systems, LLC. All rights reserved.
Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC

  • youtube
  • twitter
  • linkedin